UNITÉ DE FABRICATION DES MÉDICAMENTS S.A |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.22 TND | -0.28% |
|
+0.42% | -3.48% |
| Sales 2023 * | 134M 42.7M | Sales 2024 * | 141M 44.93M | Capitalization | 231M 73.63M |
|---|---|---|---|---|---|
| Net income 2023 * | 16M 5.1M | Net income 2024 * | 18M 5.74M | EV / Sales 2023 * | 2.18 x |
| Net Debt 2023 * | 61.1M 19.47M | Net Debt 2024 * | 66.6M 21.22M | EV / Sales 2024 * | 2.11 x |
| P/E ratio 2023 * |
12.4
x | P/E ratio 2024 * |
11.6
x | Employees | 572 |
| Yield 2023 * |
6.93% | Yield 2024 * |
7.62% | Free-Float | 29.98% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.28% | ||
| 1 week | +0.42% | ||
| Current month | -0.14% | ||
| 1 month | -0.69% | ||
| 3 months | +0.42% | ||
| 6 months | -6.84% | ||
| Current year | -3.48% |
1 week
7.13
7.30
1 month
7.127.39
Current year
6.927.56
1 year
6.858.28
3 years
6.618.28
5 years
6.6110.95
10 years
6.6111.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 88-12-31 | |
| Director of Finance/CFO | - | - | |
Imen Charfeddine
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 88-12-31 | |
| Director of Finance/CFO | - | - | |
Salah Ben Turkia
BRD | Director/Board Member | - | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 7.22 | -0.28% | 297 |
| 24-04-25 | 7.24 | -0.69% | 180 |
| 24-04-24 | 7.29 | -0.14% | 3,724 |
| 24-04-23 | 7.3 | +1.96% | 5,006 |
| 24-04-22 | 7.16 | -0.42% | 1,688 |
End-of-day quote Tunis, April 25, 2024
More quotes
Unimed (Unité de Fabrication de Médicaments) is one of the leading pharmaceutical groups in Tunisia. The activity is organized around 2 families of products:
- generic medicines: primarily infusion and inhalation products, ophthalmic products, injectable liquids and powders;
- fashioned medicines: medicines manufactured for third parties.
Sector
Pharmaceuticals
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.22
TND
Average target price
11.9
TND
Spread / Average Target
+64.82%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.48% | 73.8M | |
| +25.53% | 661B | |
| +26.74% | 566B | |
| -6.67% | 352B | |
| +19.91% | 332B | |
| +3.01% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -5.25% | 145B |
- Stock Market
- Equities
- UMED Stock
